Focal therapy (FT) is an increasingly performed treatment option in selected patients with localized prostate cancer (PCa) [1]. The aim of FT is the local eradication of all known cancerous tissue, while providing less side effects than the standard procedures radical prostatectomy and radiotherapy. High-intensity focused ultrasound (HIFU) is one of the established FT modalities with the option of focal-, hemi- or whole gland ablation [2,3].